Epstein Files Full PDF

Review waiting, please be patient. This may take 7 weeks or more, since drafts are reviewed in no specific order. There are 2,602 pending submissions waiting for review. If the submission is accepted, then this page will be moved into the article space. If the submission is declined, then the reason will be posted here. In the meantime, you can continue to improve this submission by editing normally. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Reviewer tools Instructions · What links here · Conrad Mir (talk: + · bio) · (log) · Copyvios report · reFill · Citation Bot · (Search: Google, Wikipedia) · Submitted 9 days ago by IA ResearchEditor (talk: D · +) · Last edited 9 days ago by IA ResearchEditor

Conrad F. Mir (born October 2, 1968) is an American business executive, entrepreneur, and investor who serves as President and Chief Executive Officer of Calmare Therapeutics Incorporated (OTC: CTTC),^[1][2] a medical device company focused on breakthrough chronic neuropathic pain management technologies. Since joining the company in 2013, the company has expanded its operations in non-invasive pain therapy, secured over $100 million in U.S. government contracts,^[3][4][5] and established the company as a key supplier of a Non-Addictive, Non-Invasive, Non-Narcotic, Non-Anti-Convulsant modality (NAINAC™) to the U.S. military healthcare system.^[6] Recognized as an influential thought leader in the biotechnology and medical device space, Mir was named among the Top 10 CEOs of 2023 by Industry Tech Outlook. His leadership philosophy centers on transformative innovation and strategic partnerships that advance patient care while delivering sustainable growth.

Mir was born in Jersey City, New Jersey, in 1968, of Cuban immigrants who fled the Castro regime, seeking freedom and opportunity in America.^[7]His paternal roots trace back to the Hapsburg Empire and his ancestor’s involvement in the Battle of Mir and later the family’s immigration to Cuba evading Nazi Germany and settling in Mir Village in the municipality of Calixto García, in Holguín Province. His maternal roots trace back to the Diaz lineage and the Spanish Empire.

Mir attended Xavier High School in New York City, where he excelled academically and developed early leadership skills. ^[8]He earned dual bachelor's degrees in Economics and English, with concentrations in Mathematics and Physics, from New York University.During his undergraduate years, he was a Founding Father of the Tau Alpha chapter of Tau Kappa Epsilon Fraternity at NYU.

His academic excellence earned him a corporate sponsorship from Nomura Securities International for his MBA from Columbia University's Graduate School of Business,^[9]where he specialized in Corporate Finance and Strategic Management.

Mir began his career in 1986 in the fixed-income group at Nomura Securities International, one of Japan's premier investment banks.^[10] Over his tenure in financial services, he held progressively senior roles at First Liberty Investment Group, Anne McBride & Company, and Arotech Corporation, building expertise in complex financial analysis, investor relations, and strategic advisory services for public companies.

At D.F. King & Company he worked in proxy advisory services and corporate restructuring, focusing on corporate governance and shareholder value creation. During this period, Mir advised on transactions totaling over $2 billion and developed a reputation for identifying undervalued companies with transformative potential.

As Chief Investment Officer at Advaxis, a clinical-stage biotechnology company, Mir led a capital-raising effort that secured over $36 million through debt and equity financing. This funding enabled the company to advance multiple Phase II clinical trials.^[11][12][13] His innovative approach to biotech financing, combining traditional equity raises with strategic partnerships and government grants, became a model studied by other emerging companies in the sector.

As Chairman and CEO of Genetic Immunity, Mir led a transformative corporate restructuring. This transformation required navigating intricate regulatory frameworks across multiple jurisdictions while maintaining operational continuity, and secured $3 million in PIPE (Private Investment in Public Equity) financing and additional U.S. government funding.

As Chief Financial Officer at Pressure BioSciences, a company developing innovative laboratory instrumentation, Mir implemented an operational restructuring that improved gross margins by 40% and reduced operational costs by 25%. He led capital-raising efforts through structured financing arrangements, providing the company with the resources needed for product development and market expansion.

In October 2013, Mir was appointed President, CEO, and Board member of Competitive Technologies, Inc., which he strategically repositioned and renamed Calmare Therapeutics Incorporated (Calmare). ^[14]He also served as interim CFO during the transition period.

Under Mir's leadership, Calmare is a medical device company specializing in non-invasive chronic pain management technology.

Led the advancement of Calmare's proprietary Calmare® Therapy™, a Non-Addictive, Non-Invasive, Non-Narcotic, Non-Anti-Convulsant (NAINAC™) technology that is a performance and technology improvement breakthrough over Scrambler Therapy® for chronic neuropathic pain. ^[15][16]The Calmare® Pain Therapy Device received U.S. FDA 510(k) clearance (K081255) and European CE mark certification for non-invasive treatment of chronic neuropathic and oncologic pain.^[17] According to clinical studies, NAINAC has been used to treat more than 20,000 chronic pain patients, with studies reporting pain reduction in approximately 80 percent of patients.^[18][19]

Under Mir's tenure, Calmare established partnerships with medical institutions and research centers. Multiple peer-reviewed studies have been published on the use of Calmare® Therapy™ for chemotherapy-induced peripheral neuropathy (CIPN), cancer pain, failed back syndrome, and other chronic pain conditions.^[20][21]

During Mir's tenure, Calmare secured government contracts exceeding $100 million.^[22] These included a $2.5 million five-year contract from the U.S. Department of Veterans Affairs in 2020^[23] and a $15 million General Supply Order contract in 2016.^[24] The company maintains a General Services Administration (GSA) military contract for supplying devices to U.S. military hospitals and clinics.^[25] In 2017, the company gained approval to list its devices on the GSA Advantage!® web portal.^[26]

Implemented a comprehensive corporate reengineering strategy that transformed the company's operational efficiency and market positioning. Under Mir's leadership, the company uplisted its shares^[27] and expanded its commercial distribution infrastructure.

Led successful recapitalization efforts and refinanced existing company debt, strengthening the balance sheet for long-term growth.

Mir has served as an advisor to several corporations.

• Roche AG – Provided strategic counsel on investor relations and capital market strategies.^[28]
• Vodafone PLC – Advised on shareholder proxy strategy during the acquisition of Mannesmann AG.^[29][30]

Mir's approach to leadership combines strategic vision with operational excellence, emphasizing innovation that directly addresses patient needs. He has been recognized for his ability to transform underperforming companies into viable industry competitors through disciplined business plan execution and stakeholder alignment.

Throughout his tenure at Calmare Therapeutics, Mir has emerged as a leading national advocate for non-opioid, non-invasive, and non-addictive approaches to chronic pain management. At a time when opioid dependency and overdose deaths have created a public health crisis, he has consistently championed alternatives that address pain without exposing patients to the risks of addiction, tolerance, or long-term dependency.

Under his leadership, Calmare® Therapy™ NAINAC technology has been positioned as a clinically validated, drug-free solution for neuropathic and chronic pain. Mir has actively promoted NAINAC technology as a frontline alternative to opioid-based pharmacological treatments, particularly for veterans, cancer survivors, and patients suffering from long-term nerve pain.^[31] Clinical research has demonstrated that Calmare® Therapy™ can achieve significant pain reduction, with some studies showing mean pain scores decreasing from 8.4 at baseline to 2.9 after treatment, with over 50% of patients experiencing substantial relief lasting several weeks to months.^[32][33]

Beyond corporate leadership, Mir has used the Calmare NAINAC platform to help influence healthcare providers, policymakers, and institutional partners to reconsider traditional pain treatment paradigms. His professional focus has furthered treatment models that prioritize neurological modulation and regenerative recovery over opioid-based biologics, reinforcing a patient-centered and evidence-based approach to pain care.

• Top 10 CEOs of 2023 – Industry Tech Outlook
• Who's Who Among Young Entrepreneurs
• Citation in “Friends and Strangers”

Mir resides in New Jersey with his two adult daughters, whom he credits as his greatest source of inspiration and motivation. His commitment to youth development extends beyond his family. He is a successful men’s and women’s high school volleyball coach having had 2 undefeated seasons, and 2 New York City CSAA championships. Mir is a current member coach of the Garden Empire Volleyball Association (GEVA).

A Renaissance man in the truest sense of the term, Mir is a classically trained pianist who has performed several times at Carnegie Hall as a child, and is a retired piano teacher and lifetime member of the Guild of Piano Playing Auditions^[34]. He holds a black belt in TaeKwonDo from Grand Master T.S. Cho, 8th Dan Grand Master.

Mir's journey from the son of Cuban immigrants to a prominent biotechnology CEO includes leadership roles in biotechnology and medical device companies. His professional impact extends beyond individual company successes to a broader influence i.e., the medical device industry's approach to innovation and patient care. It has contributed to important conversations in prominent medical circles about alternative approaches to pain therapy, all of which are particularly relevant during today’s ongoing discussions regarding opioid alternatives. As the healthcare industry continues to evolve, Mir's leadership in combining technological innovation with strategic business acumen positions him as an influential voice in shaping the future of medical device development and patient care solutions.

Category:1968 births Category:Living people Category:American business executives Category:American chief executives Category:New York University alumni Category:Columbia Business School alumni